Precision treatment in advanced hepatocellular carcinoma

Cancer Cell. 2024 Feb 12;42(2):180-197. doi: 10.1016/j.ccell.2024.01.007.


The past decade has witnessed significant advances in the systemic treatment of advanced hepatocellular carcinoma (HCC). Nevertheless, the newly developed treatment strategies have not achieved universal success and HCC patients frequently exhibit therapeutic resistance to these therapies. Precision treatment represents a paradigm shift in cancer treatment in recent years. This approach utilizes the unique molecular characteristics of individual patient to personalize treatment modalities, aiming to maximize therapeutic efficacy while minimizing side effects. Although precision treatment has shown significant success in multiple cancer types, its application in HCC remains in its infancy. In this review, we discuss key aspects of precision treatment in HCC, including therapeutic biomarkers, molecular classifications, and the heterogeneity of the tumor microenvironment. We also propose future directions, ranging from revolutionizing current treatment methodologies to personalizing therapy through functional assays, which will accelerate the next phase of advancements in this area.

Keywords: combinational therapy; hepatocellular carcinoma; immunotherapy; molecular classification; precision oncology; targeted therapy.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Hepatocellular* / drug therapy
  • Carcinoma, Hepatocellular* / therapy
  • Humans
  • Immunotherapy / methods
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / therapy
  • Tumor Microenvironment